Preimplantation genetic testing of embryos is an option offered at Main Line Fertilty that increases the possibility of a successful pregnancy after in vitro fertilization (IVF). PGT can help identify embryos that have genetic abnormalities that can result in a miscarriage or in a genetic disorder. Additionally, genetic testing allow patients to know the sex of the embryos if they wish.
HOW PGT IS PERFORMED
To perform preimplantation genetic testing, embryologists remove a small sample of cells from the outer layer (called the trophectoderm) of a blastocyst on day 5, day 6 or day 7 of culture. The blastocyst is frozen after the sample is removed and remains at Main Line Fertility’s laboratory. The biopsy sample is sent to a laboratory for genetic testing.
Types of PGT
Screens for aneuploidy which is too few or too many chromosomes. Aneuploidy can lead to IVF failure or miscarriage and occurs randomly in embryos during development.
Diagnoses specific genetic disorders in embryos such as Cystic Fibrosis, Fragile X, Muscular Dystrophy, BRCA, Thalassemia, Tay Sachs and others.
STRUCTURAL REARRANGEMENTS (PGT-SR)
Identifies whether the embryo has a structural rearrangement of its chromosomal matter. PGT-SR can be performed to improve the chance of establishing a healthy pregnancy for people with a chromosomal translocation.
PATIENTS WHO MAY BENEFIT FROM PGT INCLUDE
- Patients over the age of 34
- Patients who have experienced repeated IVF failure
- Patients or partners who are carriers or are affected by genetic disorders that can be passed down to a child
- Patients with a history of miscarriage
- Patients who do not want to incur cryostorage fees of chromosomally abnormal embryos
- Patients who wish to reduce their risk of miscarriage and genetic abnormalities
- Patients interested in sex selection for family balancing